SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2135)2/6/2009 8:12:38 AM
From: Biotech Jim2 Recommendations  Read Replies (2) of 2173
 
Some of the companies like MRK may have balked on the lack of sufficient efficacy, but who knows until the entire data set is made public. IT is very hard to get nasal adsorption of peptides or peptoids. Menarini was able to do so with a peripherally active NK2 antagonist for GI disorders, and that compound is in later stage trials I believe. WIth vasopressin in rats, nasal delivery was shown by one group to ameliorate the symptoms of diabetes insipidus in the Brattleboro rat. But in that case it was apparently nasally transported to the midbrain. Using a peptide of the size of GLP-1 as an agonist, I would not for the moment put more than a 1% chance of success.

BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News